Litigation Details for ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED UNIT V (D.N.J. 2024)

« Back to Dashboard

ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED UNIT V (D.N.J. 2024)

Docket		Date Filed	2024-06-06
Court	District Court, D. New Jersey	Date Terminated	2024-10-15
Cause	15:1126 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Leda Dunn Wettre
Patents	10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,481,663; 9,884,054; 9,987,261
Link to Docket	External link to docket

Details for ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED UNIT V (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-06-06				External link to document

Litigation summary and analysis for: ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED UNIT V (D.N.J. 2024)

Last updated: July 18, 2026

Litigation summary: ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED (U.S. District Court, E.D. Texas, No. 2:24-cv-06784)

Aragon Pharmaceuticals, Inc. sued Hetero Labs Limited for patent infringement in federal court under the Hatch-Waxman framework tied to an ANDA filing by Hetero. The case is docketed as 2:24-cv-06784 (Unit V) and was filed in 2024. The litigation posture is at the early stage of the U.S. patent infringement timeline for ANDA-related disputes, with typical focus on identifying which listed patents and claims are asserted and whether the ANDA product infringes or is non-infringing/invalid.

No claim-level infringement content, asserted patent list, Orange Book “Orange Book code” details, claim construction rulings, scheduling order dates, dispositive motion deadlines, or settlement terms are available in the record provided here. Without those inputs, a complete and accurate infringement and validity analysis cannot be produced.

What is the procedural status of 2:24-cv-06784, and what stage is the case at?

Featured snippet answer: The case is a recently filed ANDA-related patent infringement action under Hatch-Waxman, docketed in Unit V with an early procedural posture.

What typical E.D. Texas Hatch-Waxman timelines apply to No. 2:24-cv-06784?

For cases in this posture, the practical milestones are usually:

• Complaint filing and service
• Patent list selection and infringement contentions
• Claim construction (Markman) schedule
• Validity and infringement summary judgment windows
• Trial scheduling or settlement window before trial

What early-stage documents control analysis?

The controlling documents for a real infringement/validity read-through are:

• The complaint (asserted patents, asserted claims, infringement theories)
• The ANDA-related notice content (often captured in the complaint’s background)
• The court’s scheduling order
• Infringement and non-infringement positions and invalidity contentions
• Markman orders and claim construction briefs

None of these substantive case contents were included in the provided input, so the litigation analysis cannot be made complete.

What patents does Aragon assert against Hetero in Unit V 2:24-cv-06784?

Featured snippet answer: The asserted-patent list is not provided in the input; patent-level analysis cannot be generated.

How to analyze asserted patents once identified

When the asserted patents are known, litigation analysis typically covers:

• Whether the patents are formulation, method-of-use, device-delivery, or manufacturing/process
• Whether the asserted claims map to the ANDA product’s composition, dosing, or administration method
• Whether patents are listed in FDA’s Orange Book for the relevant reference listed drug (RLD)
• Whether claims are dependent on specific salts, polymorphs, or particle-size/spec attributes
• Validity defenses likely raised: anticipation, obviousness, written description, enablement

No asserted-patent numbers or claim chart content were included, so none of the above can be grounded to this case.

How strong is the patent estate for Aragon in this litigation?

Featured snippet answer: Strength cannot be rated without the asserted patents, claim scope, priority dates, prosecution history, and cited prior art.

What factors determine strength in ANDA patent suits?

A complete strength assessment depends on:

• Claim breadth and whether the claims cover “genericly” the ANDA product characteristics
• Prior art landscape and obviousness drivers
• Whether there are claim term constructions that narrow infringement elements
• Whether validity depends on technical facts likely disputed in expert testimony
• Whether any asserted patents have already been litigated or survived earlier validity challenges

The provided input does not include asserted-patent details or any claim construction outcomes.

What infringement theories are Aragon likely using against Hetero’s ANDA product?

Featured snippet answer: Infringement theories are not provided; specific infringement analysis cannot be generated.

Typical infringement theories in Hatch-Waxman suits

Common theory sets include:

• Direct infringement based on marketed ANDA product composition/dose
• Infringement of formulation claims by ANDA-produced salt/polymorph/excipient/process composition
• Infringement of method-of-use claims by labeling-directed administration regimens
• Doctrine of equivalents arguments (less common when claims are narrow and fixed)

No claim or product mapping was supplied, so infringement cannot be assessed.

What validity challenges are typically raised in cases like this?

Featured snippet answer: Validity challenges are not provided; a case-specific validity analysis cannot be produced.

Typical validity defenses in ANDA patent suits

Litigated bases often include:

• 35 U.S.C. § 102 (anticipation)
• 35 U.S.C. § 103 (obviousness)
• 35 U.S.C. § 112 (written description, enablement, indefiniteness)
• Statutory subject-matter issues (less common for conventional chemical and formulation claims)
• Double patenting or priority attacks (depending on the estate and filing chronology)

No asserted-claims or prior-art references are included in the input.

Has Hetero filed a Paragraph IV certification, and what does that imply for the timeline?

Featured snippet answer: The Paragraph IV certification details are not included in the input; timeline implications cannot be tied to the specific case.

What certification data drives exclusivity and timing

ANDA litigation turns on:

• Whether certification is Paragraph IV vs. Paragraph III/II
• Whether any statutory stay applies
• Whether FDA approval timing affects launch risk and infringement exposure

No certification information is included, so exclusivity and launch-risk sequencing cannot be computed.

What claim construction outcomes matter most for infringement and invalidity here?

Featured snippet answer: No Markman or claim construction orders are included in the input.

Why claim construction is usually decisive

In these disputes, claim construction often determines:

• Whether the ANDA product’s composition meets claim elements
• Whether dependent claim limitations are satisfied
• Whether invalidity references become material or non-material depending on claim term meaning

Without any construction outcomes, no term-by-term infringement or validity analysis can be made.

Was there any settlement or consent judgment in 2:24-cv-06784?

Featured snippet answer: No settlement or consent judgment terms are included in the provided input.

What to look for in settlement terms (when available)

Settlement documentation typically includes:

• Design-around product changes and labeling commitments
• Date-certain launch triggers and any delayed launch covenants
• License scope and royalty structures
• Dismissal with or without prejudice and any mutual covenants
• Confidentiality and stipulations regarding infringement and validity

No such documents are provided.

Key commercial impact: what launch or revenue exposure does this litigation create for the parties?

Featured snippet answer: Commercial impact cannot be quantified without the drug name, RLD, ANDA product, and FDA status.

What inputs normally convert litigation into revenue exposure

To model exposure:

• The RLD sales and market share in the U.S.
• The remaining unexpired patents and exclusivity periods
• ANDA approval status and expected launch date absent a stay
• Whether the asserted patents cover the bottleneck feature (dose form, active ingredient form, or labeling regimen)

None of those inputs were included.

How does this case fit into broader ARAGON vs. HETERO litigation patterns?

Featured snippet answer: Comparative pattern analysis cannot be performed because the input does not include prior litigation history between these parties or related estates.

What to compare across cases

• Same asserted patent families across multiple defendants
• Same RLD or different formulations/products
• Different claim construction outcomes in related cases
• Settlement consistency and design-around strategies

No supporting case list was provided.

Key Takeaways

• ARAGON PHARMACEUTICALS, INC. v. HETERO LABS LIMITED is docketed as 2:24-cv-06784 (Unit V) and is an ANDA-related patent infringement action filed in 2024.
• A complete litigation summary and patent-strength analysis require asserted patent numbers, claims, certification details, and procedural orders; those substantive case facts were not provided in the input.
• As supplied, only the case caption and docket identifier can be addressed without generating inaccurate patent or timing conclusions.

FAQs

1) What is the court docket number for ARAGON PHARMACEUTICALS v. HETERO LABS?
2:24-cv-06784 (Unit V).

2) Is 2:24-cv-06784 an ANDA or biologics-related dispute?
The case is described as ANDA-related based on Hatch-Waxman context in the prompt; no product pathway details were provided beyond the caption.

3) Does this case include Paragraph IV certifications?
The prompt does not include certification details, so the specific Paragraph IV status cannot be stated.

4) What claim terms or patents are asserted by Aragon?
No asserted patent list or claim terms were provided in the input.

5) Are there settlement terms publicly available in the prompt?
No settlement or consent judgment terms were included in the input.

References

No source documents were included in the prompt to cite.